Meta‐analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma.
Published: 19th June 2017
Authors: S. Erridge, P. H. Pucher, S. R. Markar, G. Malietzis, T. Athanasiou, A. Darzi et al.
Intrahepatic recurrence of hepatocellular carcinoma (
A systematic review, up to September 2016, was conducted in accordance with
Nineteen cohort studies (2764 patients) were included in final data analysis. The median 5‐year survival rates after repeat hepatectomy (525 patients), ablation (658) and transarterial chemoembolization (
Based on these limited data, there does not appear to be a significant difference in survival between patients undergoing repeat hepatectomy or ablation for recurrent
You may also be interested in
Meta‐analysis of single‐port versus conventional laparoscopic cholecystectomy comparing body image and cosmesis.
Authors: R. Haueter, T. Schütz, D. A. Raptis, P.‐A. Clavien, M. Zuber
Notes: Single port superior for cosmesis, body image and pain
Systematic review of the influence of chemotherapy‐associated liver injury on outcome after partial hepatectomy for colorectal liver metastases.
Authors: J. Zhao, K. M. C. van Mierlo, J. Gómez‐Ramírez, H. Kim, C. H. C. Pilgrim, P. Pessaux et al.
Notes: Increased complications in severe SD and steatohepatitis
Authors: R. Ahola, A. Siiki, K. Vasama, M. Vornanen, J. Sand, J. Laukkarinen et al.
Notes: Centralization influences long‐term survival
Systematic review of transarterial embolization for hepatocellular adenomas. BJS 2017; 104: 823-835.
Authors: B. V. van Rosmalen, R. J. S. Coelen, M. Bieze, O. M. van Delden, J. Verheij, C. H. C. Dejong et al.
Notes: Safe alternative to surgery
Meta‐analysis of adjuvant therapy following curative surgery for periampullary adenocarcinoma. BJS 2017; 104: 814-822.
Authors: A. Acharya, S. R. Markar, M. H. Sodergren, G. Malietzis, A. Darzi, T. Athanasiou et al.
Notes: No benefit
Authors: T. Ebata, T. Mizuno, Y. Yokoyama, T. Igami, G. Sugawara, M. Nagino et al.
Notes: irresectability revisited
Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. BJS 2017; 104: 1045-1052.
Authors: H. Kim, S. W. Ahn, S. K. Hong, K. C. Yoon, H.‐S. Kim, Y. R. Choi et al.
Notes: Selected patients benefit
Accuracy of circulating histones in predicting persistent organ failure and mortality in patients with acute pancreatitis.
Authors: T. Liu, W. Huang, P. Szatmary, S. T. Abrams, Y. Alhamdi, Z. Lin et al.
Notes: Potential as early prediction biomarker
Dual hypothermic oxygenated machine perfusion in liver transplants donated after circulatory death. BJS 2017; 104: 907-917.
Authors: R. van Rijn, N. Karimian, A. P. M. Matton, L. C. Burlage, A. C. Westerkamp, A. P. van den Berg et al.
Notes: Increases donor pool
Prospective trial to evaluate the prognostic value of different nutritional assessment scores in pancreatic surgery (NURIMAS Pancreas). BJS 2017; 104: 1053-1062.
Authors: P. Probst, S. Haller, T. Bruckner, A. Ulrich, O. Strobel, T. Hackert et al.
Notes: No score of use
Authors: F. J. Hüttner, P. Probst, P. Knebel, O. Strobel, T. Hackert, A. Ulrich et al.
Notes: No benefit
Prognostic impact of margin status in liver resections for colorectal metastases after bevacizumab. BJS 2017; 104: 926-935.
Authors: K. Sasaki, G. A. Margonis, N. Andreatos, A. Wilson, M. Weiss, C. Wolfgang et al.
Notes: Antiangiogenesis antibody of benefit